Hey readers! 👋 This week brings some truly groundbreaking developments in the T1D world, from gene-edited cell transplants to advances in fully automated insulin delivery systems. It's an exciting time as researchers push the boundaries of what's possible in diabetes care! Let's dive into the latest innovations.
🔬 Research Breakthroughs
Scientists achieve breakthrough in diabetes treatment with gene-edited cell transplant — An international team performed the world's first transplant of CRISPR-modified pancreatic islet cells, allowing a 42-year-old patient to produce insulin naturally without immunosuppressants. – @appcsocialmedia
Teplizumab gets green light in the UK — This groundbreaking drug, the first licensed in the UK to slow T1D progression, trains the immune system to stop attacking pancreatic cells, potentially delaying insulin dependence by up to three years. – The Sun
UVA researchers work towards fully automated insulin delivery systems — Researchers are developing smarter algorithms that can adjust insulin dosing without manual inputs, making diabetes management more accessible for all users. – WVIR
Towards fully automated artificial pancreas systems — Advancements in artificial pancreas technology aim to improve diabetes management through automation in monitoring and insulin delivery, potentially enhancing patient outcomes and quality of life.
📊 Technology & Data
CGM Data Analysis 2.0 — A new era of glucose data analysis is emerging, moving beyond simple statistics to advanced Functional Data Analysis, machine learning, and AI that can identify complex patterns and provide personalized insights.
Personalized blood glucose prediction using meta-learning — Researchers developed BiT-MAML, a hybrid model combining Bidirectional LSTM and Transformer architectures, achieving 19.3% improvement in blood glucose prediction accuracy over standard models. – PubMed
2009 to 2023 Saw Increase in Technology Use and Glycemic Control — A study of 186,000+ participants shows significant improvements in glycemic control as CGM use rose from 5% to 57% in adults and 4% to 82% in youth with T1D, though disparities persist among minority and Medicaid-insured populations.
🔍 Early Detection & Understanding
Islet Autoantibody Testing enters mainstream healthcare — These tests are becoming standard practice for early T1D detection, potentially enabling earlier interventions and better outcomes for those at risk. – PubMed
Profiling HLA and KIR gene interactions in T1D progression — Research reveals that specific combinations of HLA and KIR genes are associated with slower T1D progression, suggesting these interactions play a crucial role in disease pathogenesis. – PubMed
📱 Devices & Apps
twiist AID System — This FDA-cleared automated insulin delivery system offers personalized diabetes management through the twiist Loop algorithm, adapting to individual glucose targets and lifestyle choices.
FreeStyle Libre 2 Plus — Australia's first 15-day CGM provides continuous glucose monitoring without finger pricks, sending real-time data to smartphones and offering optional alarms for high or low glucose levels. – Abbott
iHealth Gluco+ Wireless Smart Glucose Monitor — This FDA-cleared, compact device pairs with the iGluco app for tracking glucose readings, featuring a rechargeable battery and requiring only 0.7 microliters of blood for accurate 5-second results.
💭 Personal Perspectives
Eight years of deliberate non-compliance — A blogger reflects on eight years using the Loop automated insulin delivery system, highlighting improved quality of life and the importance of personalized diabetes management over one-size-fits-all approaches. – @RenzaS
mySugr - Diabetes Tracker Log — This diabetes management app offers a personalized dashboard for logging diet, medications, and glucose levels, with features like insulin calculators and reporting options for sharing data with healthcare providers.
That's all for this week! The future of T1D care is looking brighter with these advancements in automated systems, early detection methods, and personalized approaches. Which breakthrough are you most excited about? Hit reply to share your thoughts!
Made with ❤️ by Data Drift Press